Research
Hormonal
Semaglutide resulted in a similar reduction in body weight across frailty subgroups.
Semaglutide can be used effectively for weight management in patients with obesity-related HFpEF, regardless of frailty status.
StrongSupportsmedium confidence
Semaglutide resulted in a similar reduction in BW across frailty subgroups.
Why this rating
Based on the large RCT design of the STEP-HFpEF program.
Source
Frailty and Effects of Semaglutide in Obesity-Related HFpEF
Ambarish Pandey et al. · JACC Heart Failure · 2025
rctCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →